PATENT CLAIM ANALYSIS

Application Number: 16051612
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-06
Patent Classification: ["514", "262100"]

Abstract:
The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Claim (Index 18):
A method for treating a neurodegenerative disorder or a psychiatric disorder comprising administering a therapeutically effective amount of the pharmaceutical composition of  claim 15  to a subject in need thereof, wherein said neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease and Huntington's Disease, and said psychiatric disorder is selected from the group consisting of Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, cognitive impairment, cognitive impairment associated with schizophrenia (CIAS), and restless leg syndrome.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 96.0
- Lexical Diversity: 1.23529
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16340429', '15637920', '16033395', '15849798', '15502144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8132590745453331
- 35 USC 102 Novelty (BERT): 0.5738893259493159
- Combined Prediction Score: 0.7893220996857314
- Mean Citation Score: 404.623846
- Max Citation Score: 509.92545
- Similarity Product: 376.09209144355947

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test